跳至主要内容
临床试验/CTRI/2023/06/054258
CTRI/2023/06/054258尚未招募4 期

Efficacy and Safety of 2% Tofacitnib gel in Acral Vitiligo

Prashant Srivastava0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • ALL PATIENT HAVING ACRAL VITILIGO
  • PATIENT GIVING CONSENT

排除标准

  • Pregnant and lactating females and patients with unrealistic expectation will not be included in this
  • Patients with comorbid conditions such as tuberculosis, peptic ulcer disease, diabetes mellitus,
  • human immuno deficiency virus infection, herpes Zoster etc .
  • Concomitant treatment with topical steroids, topical calcineurin inhibitors, supplements (e.g.
  • Polypodium leucotomos and Ginkgo biloba), or phototherapy will not be allowed.
  • Patient who are not willing to participate in the study.

研究者

发起方
Prashant Srivastava

相似试验